Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluated the effect of perioperative parecoxib administration on postoperative pain, analgesic use, function recovery, inflammatory response and bleeding risk.
Non-steroid anti-inflammatory drugs are recommended for multimodal postoperative pain management.
We evaluated the effect of perioperative parecoxib administration on postoperative pain, analgesic use, function recovery, inflammatory response and bleeding risk.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Parecoxib sodium | Experimental | The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision. |
|
| Normal saline injection | Placebo Comparator | The control group received 2 mL normal saline injection at the same time point. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Parecoxib sodium | Drug | The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine. |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the Morphine consumption in each group patients | 4 hours to 6 days after the surgery |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate Patient-Controlled Intravenous Analgesia (PCIA) duration | 4 hours to 6 days after the surgery | |
| To evaluate the Visual Analog Scale (VAS) in each group patients underwent total knee arthroplasty and total hip arthroplasty | 4 hours to 6 days after the surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Testing of body temperature,routine blood examination, IL-6 and IL-10 | hospital admission and 1, 3, 6 days after the surgery |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Zhihong Wu, Prof | PUMC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Peking Union Medical College Hospital | Beijing | Beijing Municipality | 100005 | China |
Not provided
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
| ID | Term |
|---|---|
| C409945 | parecoxib |
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Normal saline injection | Drug | The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine. |
|
|
| Function recovery of knee Range of Motion (ROM) for patients received surgery | 3 and 6 days after the surgery |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |